Rallybio Corporation - Common Stock (NQ:RLYB)

17.08 +0.32 (+1.91%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

November 02, 2023

From Rallybio Corporation

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 05, 2023

Via Benzinga

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

October 03, 2023

From Rallybio Corporation

Via Business Wire

Where Rallybio Stands With Analysts ↗

September 05, 2023

Via Benzinga

Analyst Ratings for Rallybio ↗

August 10, 2023

Via Benzinga

Analyst Ratings for Rallybio ↗

July 25, 2023

Via Benzinga

The Latest Analyst Ratings for Rallybio ↗

June 26, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

September 03, 2023

From Rallybio Corporation

Via Business Wire

Rallybio to Present at Upcoming Investor Conferences in September

August 31, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 08, 2023

From Rallybio Corporation

Via Business Wire

Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference

August 02, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)

July 11, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

June 29, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

June 24, 2023

From Rallybio Corporation

Via Business Wire

Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis

June 09, 2023

From Rallybio Corporation

Via Business Wire

Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

June 07, 2023

Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for...

Via Benzinga

Rallybio to Present at the Jefferies Healthcare Conference

June 01, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Reports First Quarter 2023 Financial Results

May 09, 2023

From Rallybio Corporation

Via Business Wire

Rallybio to Present at the JMP Securities 2023 Life Sciences Conference

May 08, 2023

From Rallybio Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023 ↗

April 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis

April 06, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

April 03, 2023

From Rallybio Corporation

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

March 30, 2023

It's time for another dive into the biggest pre-market stock movers for Thursday with all the companies traders need to watch!

Via InvestorPlace

Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program ↗

March 06, 2023

Via Benzinga

Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

March 06, 2023

From Rallybio Corporation

Via Business Wire

Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

March 06, 2023

From Rallybio Corporation

Via Business Wire

EyePoint Pharma Posts Deeper Losses For Q4, Expects Cash Runway Into 2024 ↗

March 02, 2023

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million.

Via Benzinga

Rallybio to Present at Upcoming Investor Conferences in March

March 01, 2023

From Rallybio Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.